吉西他滨联合长春瑞滨方案复治对紫杉醇联合顺铂方案疗效欠佳的晚期非小细胞肺癌24例临床观察  

Clinical observation of GEM+NVB regimen in retreatment of 24 Advanced NSCLC treated by TAX+DDP regimen

作　　者：张彤[1] 任国平[1] 张振海[1] 

机构地区：[1]河南省新乡市中心医院肿瘤内科,453000

出　　处：《肿瘤研究与临床》2006年第1期24-25,共2页Cancer Research and Clinic

摘　　要：目的评价吉西他滨(GEM)联合长春瑞滨(NVB)方案复治对紫杉醇(TAX)联合顺铂(DDP)方案疗效欠佳的晚期非小细胞肺癌(NSCLC)的疗效、生存期及不良反应。方法24例既往行TAX联合DDP治疗后疗效评价为稳定或进展的晚期NSCLC患者,继续用GEM联合NVB方案治疗,两周期后评价近期疗效和不良反应。结果24例患者近期有效率29.2%,中位生存期28周,1年生存率34.3%。结论GEM联合NVB方案复治对TP方案疗效差的NSCLC患者有一定疗效,无交叉耐药性,可使患者病情进展延缓,中位生存期延长,且毒性可耐受。Objective To appraise the efficacy, survival rate and toxicity of GEM＋NVB regimen in retreatment of 24 Advanced NSCLC treated by TAX＋DDP regimen. Methods 24 patients with Advanced NSCLC received chemotherapy of GEM＋NVB regimen. We evaluate the efficacy, survival rate and toxicity after two periods. Results Among these 24 patients, there was no complete response. Rates of partial response is 29.2 %, the average survival period is 28 weeks. One year survival rate is 34.3 %. Conclusions GEM＋ NVB regimen is effective as second-line chemotherapy for the Advanced NSCLC patients that have ever been treaded by TAX＋DDP regimen.

关 键 词：吉西他滨 长春瑞滨 紫杉醇 顺铂 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]